NASDAQ:PULM - Pulmatrix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.02 -0.04 (-3.77 %)
(As of 05/20/2019 04:21 AM ET)
Previous Close$1.02
Today's Range$1.01 - $1.08
52-Week Range$0.72 - $6.90
Volume809,380 shs
Average Volume810,710 shs
Market Capitalization$8.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

Receive PULM News and Ratings via Email

Sign-up to receive the latest news and ratings for PULM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
CUSIPN/A
Phone781-357-2333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$1.27 per share

Profitability

Net Income$-20,560,000.00

Miscellaneous

Employees22
Market Cap$8.19 million
Next Earnings Date8/2/2019 (Estimated)
OptionableOptionable

Pulmatrix (NASDAQ:PULM) Frequently Asked Questions

What is Pulmatrix's stock symbol?

Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."

When did Pulmatrix's stock split? How did Pulmatrix's stock split work?

Pulmatrix's stock reverse split on Wednesday, February 6th 2019. The 1-10 reverse split was announced on Tuesday, February 5th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 5th 2019. An investor that had 100 shares of Pulmatrix stock prior to the reverse split would have 10 shares after the split.

How were Pulmatrix's earnings last quarter?

Pulmatrix Inc (NASDAQ:PULM) released its quarterly earnings data on Tuesday, February, 19th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.20) by $0.92. View Pulmatrix's Earnings History.

When is Pulmatrix's next earnings date?

Pulmatrix is scheduled to release their next quarterly earnings announcement on Friday, August 2nd 2019. View Earnings Estimates for Pulmatrix.

What is the consensus analysts' recommendation for Pulmatrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.

What are Wall Street analysts saying about Pulmatrix stock?

Here are some recent quotes from research analysts about Pulmatrix stock:
  • 1. According to Zacks Investment Research, "Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA. " (4/20/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $3.00/share is based on an equally-weighted composite of: (a) $3.49/share, as a 15x multiple of taxed and diluted $2.47 discounted back to FY18 at 30% (in line with the expected P/E multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $2.87/ share (discounted cash flow analysis using a 18% discount rate and 0.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (11/19/2018)

Has Pulmatrix been receiving favorable news coverage?

Headlines about PULM stock have trended somewhat positive on Monday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pulmatrix earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are some of Pulmatrix's key competitors?

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulmatrix investors own include Neovasc (NVCN), SCYNEXIS (SCYX), Verastem (VSTM), Evoke Pharma (EVOK), Genocea Biosciences (GNCA), MannKind (MNKD), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), ZIOPHARM Oncology (ZIOP) and TrovaGene (TROV).

Who are Pulmatrix's key executives?

Pulmatrix's management team includes the folowing people:
  • Dr. Robert W. Clarke, CEO, Pres & Director (Age 50)
  • Mr. William E. Duke Jr., CFO, Treasurer & Sec. (Age 47)
  • Dr. James M. Roach, Consultant (Age 59)
  • Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 70)
  • Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 58)

Who are Pulmatrix's major shareholders?

Pulmatrix's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.36%) and Virtu Financial LLC (0.29%). View Institutional Ownership Trends for Pulmatrix.

Which institutional investors are selling Pulmatrix stock?

PULM stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc. and Virtu Financial LLC. View Insider Buying and Selling for Pulmatrix.

How do I buy shares of Pulmatrix?

Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pulmatrix's stock price today?

One share of PULM stock can currently be purchased for approximately $1.02.

How big of a company is Pulmatrix?

Pulmatrix has a market capitalization of $8.19 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-20,560,000.00 in net income (profit) each year or ($4.98) on an earnings per share basis. Pulmatrix employs 22 workers across the globe.

What is Pulmatrix's official website?

The official website for Pulmatrix is http://www.pulmatrix.com.

How can I contact Pulmatrix?

Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]


MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel